Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

CERo Therapeutics Holdings, Inc.

Changes in Beneficial Ownership

Filed Jan 9, 2026Accepted Jan 9, 2026, 11:30 AM ESTFiling CIK 1266567Accession 0001213900-26-002951
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-01-07
Issuer
CERO THERAPEUTICS HOLDINGS, INC.
Issuer CIK
0001870404
Trading symbol
CERO

Reporting owner 1

Name
ATWOOD BRIAN G
Reporting owner CIK
0001266567
Relationship
Director
Address
CERO THERAPEUTICS HOLDINGS, INC., 201 HASKINS WAY, SUITE 230, SOUTH SAN FRANCISCO, CA, 94080

Derivative transactions

Derivative transactions · 1 reported row
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)0.0552026-01-07A · Form 41,612,099A0.002026-01-072036-01-06Common Stock1,612,0991,612,099D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Signature 1

Signed
/s/ Andrew Kucharchuk, Attorney-in-Fact
Date
2026-01-09

Company context

CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering integrates key functional attributes of both innate and adaptive immunity within a single therapeutic construct, designed to engage the body’s immune repertoire for more comprehensive tumor targeting. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells toward tumor cells through both adaptive perforin/granzyme pathways and innate engulfment mechanisms, including targeting of the TIM-4 ligand. This employs phagocytic activity to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells (“CER-T”). CERo believes the differentiated targeting properties of CER-T cells may offer advantages compared with currently approved CAR-T therapies and could potentially extend the reach of cellular immunotherapy to both hematologic malignancies and solid tumors. CERo has initiated clinical trials for its lead product candidate, CER-1236, for hematologic malignancies.

Current securities

Historical securities (7)

Recent company filings

  1. 10-Q filingNov 13, 2026
  2. Entry into a Material Definitive AgreementOct 7, 2026
  3. Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · Unregistered Sales of Equity SecuritiesAug 31, 2026
  4. 424B3 filingAug 14, 2026
  5. 10-Q filingAug 14, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.